NASDAQ:CUE Cue Biopharma (CUE) Stock Forecast, Price & News $2.32 -0.12 (-4.92%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$2.27▼$2.4450-Day Range$2.23▼$4.2052-Week Range$2.18▼$5.12Volume138,186 shsAverage Volume293,712 shsMarket Capitalization$104.31 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Cue Biopharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside259.2% Upside$8.33 Price TargetShort InterestBearish5.49% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews Sentiment0.56Based on 5 Articles This WeekInsider TradingAcquiring Shares$19,620 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.22) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector385th out of 970 stocksPharmaceutical Preparations Industry163rd out of 454 stocks 3.5 Analyst's Opinion Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.33, Cue Biopharma has a forecasted upside of 259.2% from its current price of $2.32.Amount of Analyst CoverageCue Biopharma has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.49% of the outstanding shares of Cue Biopharma have been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Cue Biopharma has recently increased by 1.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cue Biopharma is -0.58. Previous Next 2.0 News and Social Media Coverage News SentimentCue Biopharma has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cue Biopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,620.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.24% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.83% of the stock of Cue Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($1.22) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cue Biopharma (NASDAQ:CUE) StockCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More CUE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CUE Stock News HeadlinesSeptember 28, 2023 | finance.yahoo.comAcadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?September 27, 2023 | finance.yahoo.comCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 29, 2023 | Tradewins (Ad)Successful Options Trading Begins With…Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month! September 26, 2023 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDASeptember 26, 2023 | finance.yahoo.comCue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®August 30, 2023 | benzinga.comCue Biopharma And 2 Other Stocks Under $3 Insiders Are BuyingAugust 12, 2023 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 10, 2023 | msn.comCue Biopharma: Nothing Stands Out For This Cancer Immunotherapy DeveloperSeptember 29, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 10, 2023 | finance.yahoo.comInvestors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 83% over the last three yearsAugust 10, 2023 | finance.yahoo.comCue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call TranscriptAugust 10, 2023 | finance.yahoo.comQ2 2023 Cue Biopharma Inc Earnings CallAugust 10, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Cue Biopharma (CUE)August 9, 2023 | msn.comCue Biopharma GAAP EPS of -$0.29 beats by $0.01, revenue of $1.38M beats by $0.47MAugust 9, 2023 | finance.yahoo.comCue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 9, 2023 | finance.yahoo.comCue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 1, 2023 | msn.comHarmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue EstimatesJune 30, 2023 | finance.yahoo.com3 Biotech Stocks to Buy as Companies Ink Major DealsJune 15, 2023 | markets.businessinsider.comWhere Cue Biopharma Stands With AnalystsJune 15, 2023 | markets.businessinsider.comCue Biopharma (CUE) Receives a Buy from Piper SandlerJune 14, 2023 | finance.yahoo.comCue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual MeetingJune 7, 2023 | finance.yahoo.comCue Biopharma to Host Investor CallJune 6, 2023 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Cue Biopharma (CUE)June 5, 2023 | finance.yahoo.comCue Biopharma to Present at the Jefferies 2023 Global Healthcare ConferenceMay 25, 2023 | finance.yahoo.comCue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 16, 2023 | msn.comJMP Securities Reiterates Cue Biopharma (CUE) Outperform RecommendationMay 15, 2023 | finance.yahoo.comCue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingSee More Headlines Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CUE Company Calendar Last Earnings8/08/2023Today9/29/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CUE CUSIPN/A CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.33 High Stock Price Forecast$10.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+259.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,010,000.00 Net Margins-2,899.44% Pretax Margin-2,899.39% Return on Equity-95.36% Return on Assets-64.32% Debt Debt-to-Equity Ratio0.13 Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$1.25 million Price / Sales83.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book1.52Miscellaneous Outstanding Shares44,960,000Free Float40,356,000Market Cap$104.31 million OptionableNot Optionable Beta2.02 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Daniel R. Passeri J.D. (Age 62)M.Sc., MSc., CEO & Director Comp: $985.72kDr. Anish Suri Ph.D. (Age 49)Pres & Chief Scientific Officer Comp: $641.98kMs. Kerri-Ann Millar (Age 53)Chief Financial Officer Comp: $559.03kDr. Ronald D. Seidel III (Age 47)Ph.D., Co-Founder Dr. Rodolfo J. Chaparro (Age 50)Co-Founder & Sr. Advisor Dr. Steven C. Almo (Age 62)Co-Founder and Chairman of Scientific & Clinical Advisory Board George B. Zavoico Ph.D.VP of Investor Relations & Corp. Devel.Mr. Colin G. Sandercock J.D. (Age 66)MSE, Sr. VP, Gen. Counsel & Sec. Dr. Matteo Levisetti M.D. (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsVaccitechNASDAQ:VACCReviva PharmaceuticalsNASDAQ:RVPHOramed PharmaceuticalsNASDAQ:ORMPGalectin TherapeuticsNASDAQ:GALTCitius PharmaceuticalsNASDAQ:CTXRView All CompetitorsInsiders & InstitutionsBarclays PLCBought 6,917 shares on 9/21/2023Ownership: 0.029%Anish SuriBought 4,000 shares on 8/25/2023Total: $11,040.00 ($2.76/share)California State Teachers Retirement SystemBought 11,497 shares on 8/21/2023Ownership: 0.026%Nuveen Asset Management LLCBought 146,326 shares on 8/16/2023Ownership: 0.325%Goldman Sachs Group Inc.Bought 3,683 shares on 8/15/2023Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions CUE Stock - Frequently Asked Questions Should I buy or sell Cue Biopharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CUE shares. View CUE analyst ratings or view top-rated stocks. What is Cue Biopharma's stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year target prices for Cue Biopharma's stock. Their CUE share price forecasts range from $7.00 to $10.00. On average, they expect the company's share price to reach $8.33 in the next year. This suggests a possible upside of 259.2% from the stock's current price. View analysts price targets for CUE or view top-rated stocks among Wall Street analysts. How have CUE shares performed in 2023? Cue Biopharma's stock was trading at $2.85 at the beginning of the year. Since then, CUE stock has decreased by 18.6% and is now trading at $2.32. View the best growth stocks for 2023 here. When is Cue Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our CUE earnings forecast. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01. The firm earned $1.38 million during the quarter, compared to analysts' expectations of $1.21 million. Cue Biopharma had a negative trailing twelve-month return on equity of 95.36% and a negative net margin of 2,899.44%. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD). What is Cue Biopharma's stock symbol? Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE." How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cue Biopharma's stock price today? One share of CUE stock can currently be purchased for approximately $2.32. How much money does Cue Biopharma make? Cue Biopharma (NASDAQ:CUE) has a market capitalization of $104.31 million and generates $1.25 million in revenue each year. The company earns $-53,010,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. How can I contact Cue Biopharma? Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.cuebiopharma.com. The company can be reached via phone at (617) 949-2680 or via email at ir@cuebio.com. This page (NASDAQ:CUE) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.